Testimony, Comments, & Letters

;

63 HIV organizations request for updated USPSTF PrEP guidance & issuer compliance

Jul 17, 2024

We, the undersigned 62 organizations dedicated to the fight to end HIV, write to request CMS issue updated guidance in order to ensure issuer compliance with the most recent, updated United States Preventive Services Task Force (USPSTF) recommendation for HIV Pre-Exposure Prophylaxis (PrEP). As community-based organizations, advocacy groups, clinical providers, and public health practitioners working with people and communities affected by HIV, we know the urgency of ensuring broad and equitable access to PrEP free of insurance barriers.

read more

Oppose domestic HIV programs cuts of over $541 million in Labor HHS approps. bill

Jul 9, 2024

There are currently over 1.2 million people living with HIV in the United States and approximately 32,000 new diagnoses annually, with only 65 percent of people virally suppressed and only 36 percent of the people who would benefit from PrEP on it. While we are making progress, racial, ethnic, gender, and geographic disparities persist, and continued investments are needed to reduce new infections and bring more people into care and treatment.

read more

Public Comments on Potential Viral Hepatitis Quality Measures in Medicaid

Jun 7, 2024

We support the adoption of quality measures for hepatitis B and hepatitis C in Medicaid. We support the adoption of hepatitis C screening and treatment initiation measures within state Medicaid programs. We urge HHS to consider quality measures for hepatitis B screening and linkage to care, as well as for hepatitis C sustained virological response (SVR) for testing and proposal to the Medicaid Adult Core Set. We support the implementation of hepatitis B screening, hepatitis C screening, and hepatitis C treatment initiation quality measures within state Medicaid programs.

read more

Senate testimony on FY25 appropriations for HIV and hepatitis programs

May 24, 2024

Our nation can eliminate both HIV and viral hepatitis, but without investing additional resources to accelerate our efforts, we will continue to fall short of these ambitious goals. Increased investment–and certainly not cuts–in surveillance, education, prevention, and care and treatment will lead to further progress in reducing HIV and viral hepatitis, which include taking a syndemic approach to achieve maximum impact.

read more

Comments to MD Prescription Drug Affordability Board on HIV treatments

May 15, 2024

While we are supportive of the Maryland Prescription Drug Affordability Board (PDAB) goal of improving treatment affordability, we urge PDAB members and staff to address concerns surrounding access to provider-recommended HIV treatments at the individual level and the impact on broader public health goals and provide clarity around the affordability review process to enable meaningful community input.

read more

Search

Categories

Tags

ACA Appropriations Biden administration CDC co-pay accumulators Congress copay copay accumulator Copay accumulators Copay assistance Cost-sharing COVID-19 Drug Pricing FDA Gay men healthcare Hepatitis Hepatitis B hepatitis C Hepatitis Prevention HHS HIV HIV Prevention Insurers Medicaid medicare Medicare Part D NAIC NIH PBM PBMs PrEP Prescription Drugs Private Insurance Ryan White Program state STDs Syringe services Testing transparency Treatment Trump administration women

Recent Testimony, Letters, Comments

Pin It on Pinterest